Kepler Cheuvreux upgraded Bayer (BAYRY) to Buy from Hold with an unchanged price target of EUR 33. All of Bayer’s operational problems and a “good chunk of the worst-case scenario” on the litigation front are priced into shares, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer upgraded to Buy from Neutral at Goldman Sachs
- Bayer price target raised to EUR 28 from EUR 26 at Morgan Stanley
- Bayer says FDA accepts NDA under priority review for sevabertinib
- Bayer price target raised to EUR 25 from EUR 22 at Barclays
- Trump Trade: Trump considers 50% tariff on EU, 25% on iPhones